Biotron Ltd
ASX:BIT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
XANO Industri AB
STO:XANO B
|
SE |
|
Filo Mining Corp
TSX:FIL
|
CA |
|
Music Broadcast Ltd
NSE:RADIOCITY
|
IN |
|
Beijing Jiaoda Singal Technology Co Ltd
SZSE:300851
|
CN |
|
S
|
Scherzer & Co AG
XETRA:PZS
|
DE |
|
Deutsche Wohnen SE
XETRA:DWNI
|
DE |
Biotron Ltd
EPS (Diluted)
Biotron Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biotron Ltd
ASX:BIT
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
EPS (Diluted)
$0
|
CAGR 3-Years
21%
|
CAGR 5-Years
17%
|
CAGR 10-Years
12%
|
|
|
CSL Ltd
ASX:CSL
|
EPS (Diluted)
$2
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
0%
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
9%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
55%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
-100%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Biotron Ltd
Glance View
Biotron Ltd. operates as a clinical stage biotechnology company. The company is headquartered in North Ryde, New South Wales. The company went IPO on 2001-01-24. The firm is engaged in the funding and management of intermediate, and applied biotechnology research and development projects. The company is engaged in developing small molecule antiviral therapeutics targeting a range of viruses including Hepatitis C virus (HCV) and human immunodeficiency virus-1 (HIV-1). The firm's lead drug, BIT225 is in Phase II clinical development for the treatment of HIV-1 and HCV infections. BIT225 is a small-molecule anti-viral compound that works to inhibit the viroporin mechanism of Viral Protein U (Vpu). BIT225, in HIV-1, offers eradicate reservoirs of virus found in long-lived macrophage cells, which contribute to the need for life-long treatment with antiretroviral drugs. For HCV, BIT225 offers as a class of oral direct-acting antiviral (DAA) drug. The firm progresses its Hepatitis B virus (HBV) program. The company also designs and develops drugs drugs that target a class of viral proteins known as viroporins.
See Also
What is Biotron Ltd's EPS (Diluted)?
EPS (Diluted)
0
AUD
Based on the financial report for Dec 31, 2025, Biotron Ltd's EPS (Diluted) amounts to 0 AUD.
